Abstract
For more than 15 years, several combination therapies have been used in the treatment of advanced gastroesophageal cancer (GEC) raising the median survival rate from about 3 to 4 months (best supportive care) to about 8–11 months. The most important achievement was the introduction of trastuzumab in combination with 5-FU/cisplatin or capecitabine/cisplatin as first-line therapy in HER2-positive advanced GEC. Recent ASCO/CAP guidelines recommend immunohistochemical assessment as the first diagnostic step with ISH confirmation only in IHC2+ equivocal cases. Another agent (ramucirumab) has been approved for second-line therapy directed against VEGFR2 but without any biomarker. A number of other drugs targeting transmembranous growth factor receptors and downstream signaling pathways have been evaluated but so far without final results or approvals. Most promising data have recently been shown for checkpoint inhibitors using anti PD1/PD-L1 therapies where a demonstration of mismatch repair deficiency (MMRd) or immunohistochemical demonstration of PD-L1 expression seems to be of predictive value.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
World Cancer Research Fund International. Stomach cancer statistics. Retrieved from: http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/stomach-cancer-statistics.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
Lorenzen S, Riera Knorrenschild J, Haag GM, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51:569–76.
Tabernero J, Hoff P, Shen L, et al. Pertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): final analysis of a phase III study (JACOB). Ann Oncol. 2017;28(suppl_5):v209–68.
Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–53.
Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:446–64.
Doucet L, Terris B, Chenard MP, et al. Concordance of HER2 status between local and Central Review in Gastric (GC) and gastroesophageal Junction Cancers (GEJC): a French observational study of 394 specimens: HERable study. Mod Pathol. 2016;29:170A. (Abstract 671).
Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299–307.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
Cetin B, Gumusay O, Cengiz M, Ozet A. Advances of molecular targeted therapy in gastric cancer. J Gastrointest Cancer. 2016;47:125–34.
Shah MA, Cho JY, Tan IB, et al. A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction. Oncologist. 2016;21:1085–90.
Marx AH, Zielinski M, Kowitz CM, et al. Homogeneous EGFR amplification defines a subset of aggressive Barrett’s adenocarcinomas with poor prognosis. Histopathology. 2010;57:418–26.
Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer. 2009;100:298–304.
Fuchs CS, Doi T, Woo-Jun Jang R, et al. KEYNOTE-059 cohort 1: efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. JCO. 2017;35(suppl):4003. (Abstract 4003).
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461–71.
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
Setia N, Agoston AT, Han HS, et al. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29:772–84.
Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rüschoff, J. (2019). Predictive Markers and Targeted Therapies in Gastroesophageal Cancer (GEC). In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_39
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_39
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)